Pfizer, GSK US RSV Vaccine Uptake Likely Hurt By ACIP’s Weaker Recommendation

Price tag, inadequate trial designs, safety and questions about possibility of boosters were among the reasons CDC advisors voted that adults 60 and over ‘may’ receive an RSV vaccine. A stronger ‘should’ receive RSV vaccine had seemed possible for the over 65 group earlier this year.